Physician profile
Timothy D Dibble
NPI 1508936212
$3,017.71
in general payments reported to CMS, 2019-2025
25 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $382 · 2021: $643 · 2022: $632 · 2023: $334 · 2024: $206 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $468.44 | 2019-2023 | Belbuca |
| Abbvie INC. | $405.89 | 2021-2025 | Botox, Qulipta |
| Daiichi Sankyo INC. | $354.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.20 | 2019-2024 | Relistor |
| Lilly USA, LLC | $180.24 | 2019-2023 | Emgality |
| Pacira Therapeutics, INC. | $163.97 | 2019-2020 | |
| Pfizer INC. | $139.41 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $134.53 | 2021 | |
| Nevro Corp. | $123.11 | 2022 | |
| Boston Scientific Corporation | $122.86 | 2021-2025 | General - Pain Management |
| Biodelivery Sciences International, INC. | $119.82 | 2020-2021 | |
| Allergan, INC. | $93.04 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $79.44 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $78.86 | 2022-2023 | Dysport |
| Abbott Laboratories | $42.50 | 2021-2023 | Proclaim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $41.53 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $34.98 | 2020 | |
| Amgen INC. | $31.51 | 2021-2022 | |
| Bioventus LLC | $31.32 | 2019 | |
| Nalu Medical, INC. | $29.48 | 2023 | Nalu Neurostimulation System |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.38 | 2022 | |
| Averitas Pharma INC. | $26.59 | 2024 | Qutenza |
| Mdd US Operations, LLC | $24.65 | 2019 | |
| Radius Health, INC. | $20.37 | 2022 | |
| Hikma Pharmaceuticals USA | $17.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Dibble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.